Personalized medicine

What’s in it for rare diseases?

Sebastian Schee Genannt Halfmann, Laura Mählmann, Lada Leyens, Matthias Reumann, Angela Brand

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages387-404
Number of pages18
DOIs
Publication statusPublished - 01-01-2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1031
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Precision Medicine
Rare Diseases
Medicine
Delivery of Health Care
Cardiology
Patient Participation
Oncology
Nutrition
Innovation
Health
Technology
Research
Pharmaceutical Preparations
Big data

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Schee Genannt Halfmann, S., Mählmann, L., Leyens, L., Reumann, M., & Brand, A. (2017). Personalized medicine: What’s in it for rare diseases? In Advances in Experimental Medicine and Biology (pp. 387-404). (Advances in Experimental Medicine and Biology; Vol. 1031). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_22
Schee Genannt Halfmann, Sebastian ; Mählmann, Laura ; Leyens, Lada ; Reumann, Matthias ; Brand, Angela. / Personalized medicine : What’s in it for rare diseases?. Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. pp. 387-404 (Advances in Experimental Medicine and Biology).
@inbook{05b6792a6df44b2287cbc76d8c6954ca,
title = "Personalized medicine: What’s in it for rare diseases?",
abstract = "Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.",
author = "{Schee Genannt Halfmann}, Sebastian and Laura M{\"a}hlmann and Lada Leyens and Matthias Reumann and Angela Brand",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-67144-4_22",
language = "English",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "387--404",
booktitle = "Advances in Experimental Medicine and Biology",

}

Schee Genannt Halfmann, S, Mählmann, L, Leyens, L, Reumann, M & Brand, A 2017, Personalized medicine: What’s in it for rare diseases? in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1031, Springer New York LLC, pp. 387-404. https://doi.org/10.1007/978-3-319-67144-4_22

Personalized medicine : What’s in it for rare diseases? / Schee Genannt Halfmann, Sebastian; Mählmann, Laura; Leyens, Lada; Reumann, Matthias; Brand, Angela.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. p. 387-404 (Advances in Experimental Medicine and Biology; Vol. 1031).

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Personalized medicine

T2 - What’s in it for rare diseases?

AU - Schee Genannt Halfmann, Sebastian

AU - Mählmann, Laura

AU - Leyens, Lada

AU - Reumann, Matthias

AU - Brand, Angela

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

AB - Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

UR - http://www.scopus.com/inward/record.url?scp=85037663316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037663316&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-67144-4_22

DO - 10.1007/978-3-319-67144-4_22

M3 - Chapter

T3 - Advances in Experimental Medicine and Biology

SP - 387

EP - 404

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -

Schee Genannt Halfmann S, Mählmann L, Leyens L, Reumann M, Brand A. Personalized medicine: What’s in it for rare diseases? In Advances in Experimental Medicine and Biology. Springer New York LLC. 2017. p. 387-404. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-67144-4_22